Payment overview · 2025
General Payments
$640.89
30 reported records · 13 companies
Healthcare provider profile · identity verified
John M Lee, MD
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology · MILTON, FL · NPI 1245276088
Verified facts
What the public records show
CMS Open Payments records show John M Lee, MD received $640.89 in general payments during 2025 across 30 reported records.
Axsome Therapeutics, Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DUAVEE as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Duavee by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $142.16 | 22.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.30 | 11.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.75 | 9.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.13 | 8.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.41 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.96 | 7.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $45.04 | 7.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.74 | 5.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.07 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.05 | 4.8% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.80 | 3.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $20.43 | 3.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.05 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $640.89 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $142.16 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $74.30 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.13 | 3 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $54.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.96 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $45.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.74 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $32.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | DUAVEE open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1228986920 |
Duavee · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 169 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 52 |
| Ozempic | Semaglutide | 151 | 23 |
| Alprazolam | Alprazolam | 141 | 27 |
| Potassium Chloride | Potassium Chloride | 140 | 52 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 129 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 119 | 21 |
| Omeprazole | Omeprazole | 113 | 37 |
| Prednisone | Prednisone | 112 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 35 |
| Lisinopril | Lisinopril | 94 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 93 | 31 |
| Furosemide | Furosemide | 93 | 36 |
| Spironolactone | Spironolactone | 92 | 26 |
| Diazepam | Diazepam | 89 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 36 |
| Methylprednisolone | Methylprednisolone | 83 | 54 |
| Losartan Potassium | Losartan Potassium | 82 | 29 |
| Pregabalin | Pregabalin | 81 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 30 |
| Synthroid | Levothyroxine Sodium | 77 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 25 |
| Mounjaro | Tirzepatide | 72 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 12 |
| Xyosted | Testosterone Enanthate | 66 | suppressed |
| Duavee | Estrogens,conj/Bazedoxifene | 64 | 21 |
| Lorazepam | Lorazepam | 59 | 13 |
| Methadone Hcl | Methadone Hcl | 58 | suppressed |
| Meloxicam | Meloxicam | 57 | 23 |
| Fluconazole | Fluconazole | 54 | 34 |
| Estradiol | Estradiol | 53 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 15 |
| Cefuroxime | Cefuroxime Axetil | 51 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 28 |
| Tramadol Hcl | Tramadol Hcl | 51 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 17 |
| Promethazine Hcl | Promethazine Hcl | 48 | 22 |
| Buprenorphine Hcl | Buprenorphine Hcl | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 18 |
| Metformin Hcl Er | Metformin Hcl | 46 | 19 |
| Carvedilol | Carvedilol | 45 | 13 |
| Clonidine Hcl | Clonidine Hcl | 45 | 18 |
| Clonazepam | Clonazepam | 42 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | 15 |
| Montelukast Sodium | Montelukast Sodium | 42 | 16 |
| Ondansetron Odt | Ondansetron | 42 | 19 |
| Simvastatin | Simvastatin | 41 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 16 |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Doxepin Hcl | Doxepin Hcl | 35 | 20 |
| Linzess | Linaclotide | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Ibuprofen | Ibuprofen | 33 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Metolazone | Metolazone | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Naltrexone Hcl | Naltrexone Hcl | 18 | 18 |
| Roflumilast | Roflumilast | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $640.89 · 30 records | Axsome Therapeutics, Inc. | ACCRUFER, AIRSUPRA, APTIMA, Auvelity, ELIQUIS, LUX-Dx Insertable Cardiac Monitor, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VYEPTI, WAKIX, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error